More Drug Industry Fees On The Way? MA Plan Amendment May Call For Bigger Contribution From Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Florida Sen. Nelson would pay for Medicare Advantage plan proposal with more fees from drug makers, insurers.
You may also be interested in...
Health Care Reform Markups In Brief
PBM transpanancy amendment adopted: An amendment requiring certain data from pharmacy benefit managers working with plans operating in the health insurance exchange that would be created under reform legislation was adopted during markup in the Senate Finance Committee. The amendment, introduced by Sen. Maria Cantwell, D-Wash., would require PBMs to disclose to the exchange plans that they contract with the percent of all prescriptions that are provided through retail and mail-order pharmacies and the generic dispensing and substitution rates at each location; the aggregate amount and types of rebates, discounts and price concessions PBMs negotiate on behalf of plan sponsors and how much of that amount is passed through to the plan sponsors; and the average aggregate difference between the amount the plan pays the PBM and the amount the PBM pays the retail and mail-order pharmacy. Cantwell said the amendment is not expected to require an offset, but the Pharmaceutical Care Management Association, which represents PBMs, said previous Congressional Budget Office scores of similar language could increase drug costs as much as $10 billion
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.